-
公开(公告)号：EP4446309A3
公开(公告)日：2025-01-08
申请号：EP24176618.7
申请日：2020-01-09
Applicant: Eisai R&D Management Co., Ltd.
Inventor： FANG, Francis G. , MITASEV, Branko , YANG, Jiong
IPC: C07D487/04 , C07D491/147 , C07D203/12 , C07D205/04 , C07D307/33 , C07D317/28 , C07C229/36 , C07C247/10 , C07C231/12 , C07C303/40 , C07C313/06
Abstract: A method for the synthesis of diazabicyclo[6.2.0]decane compounds is provided. The synthesis proceeds by stereoselective synthesis of a chiral lactone followed by azetidine formation via a series of chemoselective reactions. Bicyclization results with the formation of diazobicyclo[6.2.0]decane related compounds.
-
公开(公告)号：EP4403560A3
公开(公告)日：2024-10-23
申请号：EP23217658.6
申请日：2018-11-15
Inventor： KISHI, Yoshito , KIRA, Kazunobu , ITO, Ken
IPC: C07D493/22 , A61P35/00 , A61K31/357
Abstract: The present invention provides novel compounds ( e.g ., compounds of Formulae ( I ), ( II ), ( III ), ( IV )) having tumor vascular remodeling effect and/or anti-CAF (Cancer Associated Fibroblasts) activity, or pharmaceutically acceptable salts thereof, optionally in a pharmaceutically acceptable carrier, and a medical uses thereof.
-
公开(公告)号：EP4446309A2
公开(公告)日：2024-10-16
申请号：EP24176618.7
申请日：2020-01-09
Applicant: Eisai R&D Management Co., Ltd.
Inventor： FANG, Francis G. , MITASEV, Branko , YANG, Jiong
IPC: C07C247/10
Abstract: A method for the synthesis of diazabicyclo[6.2.0]decane compounds is provided. The synthesis proceeds by stereoselective synthesis of a chiral lactone followed by azetidine formation via a series of chemoselective reactions. Bicyclization results with the formation of diazobicyclo[6.2.0]decane related compounds.
-
公开(公告)号：EP4403560A2
公开(公告)日：2024-07-24
申请号：EP23217658.6
申请日：2018-11-15
Inventor： KISHI, Yoshito , KIRA, Kazunobu , ITO, Ken
IPC: C07D493/22 , A61P35/00 , A61K31/357
CPC classification number: C07D493/22 , A61P35/00
Abstract: The present invention provides novel compounds (e.g., compounds of Formulae (I), (II), (III), (IV)) having tumor vascular remodeling effect and/or anti-CAF (Cancer Associated Fibroblasts) activity, or pharmaceutically acceptable salts thereof, optionally in a pharmaceutically acceptable carrier, and a medical uses thereof.
-
公开(公告)号：EP4330394A2
公开(公告)日：2024-03-06
申请号：EP22723925.8
申请日：2022-04-28
Applicant: Eisai R&D Management Co., Ltd.
Inventor： VATHIPADIEKAL, Vinod , MITASEV, Branko , EASLEY-NEAL, Courtney , CHOI, Hyeong Wook , FANG, Frank , WANG, John , VEMULA, Praveen , LEE, Jung Hwa
IPC: C12N15/113 , A61K31/712 , A61K31/7125 , A61P25/28
-
Patent Agency Ranking
公开(公告)号：EP4252851A3
公开(公告)日：2023-11-22
申请号：EP23174369.1
申请日：2015-06-17
Applicant: Epizyme Inc , Eisai R&D Management Co., Ltd.
Inventor： KEILHACK, Heike , OTTESEN, Lone , REYDERMAN, Larisa , JOHNSTON, L. Danielle , KNUTSON, Sarah K.
IPC: A61K31/4412 , A61K31/5377 , A61K31/444 , A61P35/00 , A61P35/02
Abstract: The present invention relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and their use for the treatment of cancer.
-
公开(公告)号：EP4268847A1
公开(公告)日：2023-11-01
申请号：EP21910847.9
申请日：2021-12-22
Applicant: Eisai R&D Management Co., Ltd
Inventor： TASHIRO, Katsuhisa , TAGUCHI, Ryota
IPC: A61K39/395 , A61P25/00 , C07K16/40 , C12N15/13
Abstract: A novel pharmaceutical composition for treating ALS is provided comprising as the active ingredient an anti-EphA4 antibody that can bind to EphA4 and enhance the cleavage of EphA4. A pharmaceutical composition for treating ALS comprising an anti-EphA4 antibody is provided, wherein the anti-EphA4 antibody comprises a heavy chain comprising a heavy chain CDR1 consisting of the amino acid sequence shown in SEQ ID NO. 44, a heavy chain CDR2 consisting of the amino acid sequence shown in SEQ ID NO. 27, and a heavy chain CDR3 consisting of the amino acid sequence shown in SEQ ID NO. 28, and a light chain comprising a light chain CDR1 consisting of the amino acid sequence shown in SEQ ID NO. 29, a light chain CDR2 consisting of the amino acid sequence shown in SEQ ID NO. 30, and a light chain CDR3 consisting of the amino acid sequence shown in SEQ ID NO. 31.
-
公开(公告)号：EP4218820A3
公开(公告)日：2023-09-20
申请号：EP23159590.1
申请日：2018-03-16
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Karr, Craig D. , Korpal, Manav , Rioux, Nathalie , Smith, Peter Gerard
IPC: A61K45/06 , A61K31/445 , A61K31/519 , A61P35/00
Abstract: Provided herein is a combination therapy useful for the treatment breast cancer. The combination comprises an ER-alpha inhibitor and a CDK 4/6 inhibitor.
-
公开(公告)号：EP4240360A1
公开(公告)日：2023-09-13
申请号：EP21824708.8
申请日：2021-11-03
Applicant: Eisai R&D Management Co., Ltd.
Inventor： GUALBERTO, Antonio , SCHOLZ, Catherine , XIAO, Jianjun
IPC: A61K31/496 , A61P35/02 , A61P43/00
-
公开(公告)号：EP4169924A2
公开(公告)日：2023-04-26
申请号：EP22214189.7
申请日：2018-07-06
Inventor： FUKUYAMA, Takashi , KISHI, Yoshito , AI, Yanran , YE, Ning , WANG, Qiaoyi , YAHATA, Kenzo , ISO, Kentaro , NAINI, Santhosh Reddy , YAMASHITA, Shuji , LEE, Jihoon , OHASHI, Isao
IPC: C07D493/22 , C07D493/04
Abstract: The present invention provides methods for the synthesis of ketones involving a Ni/Zr-mediated coupling reaction. The Ni/Zr-mediated ketolization reactions can be used in the synthesis of halichondrins (e.g., halichondrin A, B, C; homohalichondrin A, B, C; norhalichondrin A, B, C), and analogs thereof. Therefore, the present invention also provides synthetic methods useful for the synthesis of halichondrins, and analogs thereof. Also provided herein are compounds (i.e., intermediates) useful in the synthesis of halichondrins, and analogs thereof. In particular, the present invention provides methods and compounds useful in the synthesis of compound of Formula (H3-A):
-
-
-
-
-
-
-
-
-
Search Results
867
records
(took 0.028 seconds)
